Prevention or mitigation of T-cell bispecific antibody-associated adverse reactions
The present invention relates to the prevention or mitigation of adverse reactions associated with T cell bispecific antibodies, such as cytokine release syndrome. In particular, the present invention relates to the prevention or alleviation of side effects arising from the use of tyrosine kinase inhibitors such as dasatinib..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Europäisches Patentamt - (2023) vom: 23. Juni Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
HEIGL HANS CHRISTIAN [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Sonstige Themen: |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-06-23, Last update posted on www.tib.eu: 2024-03-04, Last updated: 2024-03-08 |
|---|
| Patentnummer: |
CN116322691 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA01761807X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA01761807X | ||
| 003 | DE-627 | ||
| 005 | 20240308101253.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230714s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA01761807X | ||
| 035 | |a (EPA)CN116322691 | ||
| 035 | |a (EPA)78000677 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a HEIGL HANS CHRISTIAN |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prevention or mitigation of T-cell bispecific antibody-associated adverse reactions |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2023-06-23, Last update posted on www.tib.eu: 2024-03-04, Last updated: 2024-03-08 | ||
| 520 | |a The present invention relates to the prevention or mitigation of adverse reactions associated with T cell bispecific antibodies, such as cytokine release syndrome. In particular, the present invention relates to the prevention or alleviation of side effects arising from the use of tyrosine kinase inhibitors such as dasatinib. | ||
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a KLEIN CHRISTIAN |4 aut | |
| 700 | 0 | |a LECLERC GILLES |4 aut | |
| 700 | 0 | |a TOSO ANDREA |4 aut | |
| 700 | 0 | |a ZIMMERMANN TRACY |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 23. Juni |
| 773 | 1 | 8 | |g year:2023 |g day:23 |g month:06 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/78000677/publication/CN116322691A1?q=CN116322691 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 23 |c 06 | ||